ductal carcinoma

[Journal of Molecular Diagnostics] The authors provide an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multi-gene assays for invasive breast cancer and ductal carcinoma in situ, and companion tests to detect PIK3CA mutations and NTRK fusions.

[Scientific Reports] Investigators made use of a clonal beta cell line (1.1B4) available from the European Collection of Authenticated Cell Cultures, which had been generated by the fusion of primary human beta-cells with a pancreatic ductal carcinoma cell, PANC-1.

[Cancer Research] Scientists CRISPR-engineered RNA splice junctions to produce normal and early stage ductal carcinoma in situ breast epithelial cells that expressed only AIB1Δ4. These cells showed enhanced motility and invasion in 3D cell culture.

[npj Breast Cancer] Patients with high-risk DCIS were enrolled in this 3×3 Phase I dose-escalation pilot study of two, four and eight mg intralesional injections of the PD-1 immune checkpoint inhibitor, pembrolizumab.

[Oncogene] The authors investigated the contribution of nucleoside diphosphate kinase (NME1), a known metastasis suppressor, to local invasion in breast cancer.

[npj Breast Cancer] Scientists identified tumour antigens in mice that were important in the survival of HER2 positive and triple negative human breast cancer cell lines, suggesting them as potential early diagnostic markers in human breast tumors.